Drug intelligence / Profile preview

TOTUM•070

Development stage
Unknown
Lead developer
Valbiotis
Modality
Small Molecules
Administration
Oral
01

Overview

TOTUM•070 is a patented, polyphenol-rich active substance composed of a blend of five plant extracts. It is developed as a clinically validated, non-pharmaceutical dietary supplement for the management of mild to moderate hypercholesterolemia. The product has demonstrated significant lipid-lowering effects in both preclinical and clinical studies, including reductions in LDL cholesterol, total cholesterol, non-HDL cholesterol, and triglycerides. Its mechanism involves multi-targeted actions at both the intestinal level (reducing cholesterol absorption) and hepatic level (inhibiting de novo cholesterol synthesis), with additional benefits on liver health such as decreased lipid storage and reduced expression of inflammatory markers. The supplement also positively modulates gut microbiota composition. Developed by Valbiotis, it is intended for over-the-counter use without prescription and targets individuals not eligible or recommended for pharmaceutical statins or other drug therapies[1][2][3][5][6][7].

Brand names
TOTUM•070
Other names
T070T-070T 070TOTUM-070TOTUM070TOTUM 070
02

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)FASN (Fatty acid synthase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CYP7A1 (Cholesterol 7alpha-hydroxylase)LCAT (Lecithin-cholesterol acyltransferase)

Beyond the preview

Go deeper on TOTUM•070.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOTUM•070.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call